Replies to post #17384 on RespireRx Pharmaceuticals Inc (RSPI)

[atheroprevent]

Gfp, I think the word from the experts just hasn't gotten out. A lot of bettors still remember bad info from R+R. Most remember the breakdown at the FDA psychiatry hurdle, but that will not be in play in this race.

[myostrain]

I think the implied experts were some of this board. Typical investors and investment funds will not take more than a blink of time at Cortex soley due to the share price and market cap.
R+Rs sp forecast for .30's, cash on hand, market cap, revenue, timeline proximity to revenue,, all adds to a very small group of people or companies with awareness of Cortex and some of those companies may not want to help spike the sp if they want to work on a deal.